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Activation of the human plasma kallikrein enzyme system results in the production 
of  pharmacologically potent  polypeptides known  as  kinins.  These  substances,  in 
nanogram  quantities,  produce  vasodilation,  incite  pain,  increase  vascular  perme- 
ability, stimulate leukotaxis, and  act on  uterine and  intestinal smooth  muscle  (1). 
The role of the kallikrein system in human disease is becoming more apparent (1-3). 
The plasma of patients with  hereditary angioneurotic edema has been found  to be 
deficient in  C1  inactivator  ~ (5,  6)  an  a  2-neuraminoglycoprotein which  in purified 
systems  inhibits kallikrein, C1  esterase,  PF/dil  and  plasmin  (5,  7-9).  In  patients 
lacking this inhibitor, C1 activation has been demonstrated in vivo during attacks of 
angioedema (10,  11). The evidence for activation of the kaUikrein system under similar 
circumstances is less convincing than that obtained for the complement system. As a 
consequence, it has been suggested that there may be other physiologically  important 
inhibitors of plasma kallikrein (12). 
In the present study, examination of the kinetics of kaolin-induced activation 
of plasma kallikrein esterolytic activity (13-15) in normal plasma and in plasma 
from patients with hereditary angioneurotic edema has indicated that a protein 
other than Ci inactivator is a  major plasma inhibitor of kallikrein. This inhib- 
itor has been identified as the plasma o~ 2-macroglobulin and has been shown to 
inhibit both the esterolytic and kinin-producing activities of plasma kallikrein. 
Materials 
Substrates.--N-acetyl-L-tyrosine ethyl  ester  (ATEe), 2  N'-c~-acetyl-L-lysine methyl  ester 
(ALMe), N-benzoyl-L-arginine methyl ester (BAMe) and tosyl arginine methyl ester (TAMe) 
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03346 (National Institute of Neurological  Diseases  and Blindness,  Bethesda, Md.), and in 
part by contract No. PH-43-67-1439 with the National Institutes of Health. 
:~ American Cancer  Society Research  Scholar. 
1 The complement  terminology used in this report conforms to  the nomenclature  adopted 
in the World Health Organization Bulletin (4). In the new terminology,  C1 inacfivator re- 
places C'I esterase inhibitor. C1 designates the activated first component  of complement and 
Cls the activated subcomponent  of Ci. 
2Abbreviations used in  this paper:  ALMe,  N-c~-acetyl-L-lysine methyl  ester;  BAMe, 
N-benzoyl-L-arginine  methyl  ester;  BAPNA,  benzoyl-DL-arginine-p-nitroanilide;  HANE, 
hereditary angioneurotic  edema;  PEG,  polyethylene glycol;  PTA,  plasma thromboplastin 
antecedent; SBTI, soybean trypsin inhibitor; TAMe, tosyl arginine methyl ester. 
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were obtained from Cyclo Chemical Corp., Los Angeles,  Calif.  Benzoyl-DL-arginine-p-nitro- 
anilide (BAPNA) was obtained from Mann Research Laboratories, Inc. New York. 
Soybean Trypsin  Inhibitor.--Crude  and  purified soybean trypsin inhibitor  preparations 
(SBTI) were obtained from Worthington Biochemical Corp., Freehold, N. J.  The concentra- 
tion of purified SBTI used in various experiments was calculated by determining the optical 
density of the SBTI solution at 280 m/z. This value was multiplied by 1.1 to convert it to the 
concentration of SBTI expressed in milligrams per milliliter (16). 
Bradykinin  triacetate (Calbiochem,  Los Angeles,  Calif.)  was dissolved in 0.15  M sodium 
chloride and stored at -20°C. 
Plasma.--Blood  from normal  individuals,  from patients with hereditary angioneurotic 
edema, and from an  individual with plasma  thromboplastin antecedent (PTA)  deficiency 
was collected in plastic syringes and placed in a/~ volume of 3.8% sodium citrate in polypro- 
pylene test tubes. Plasma was obtained following centrifugation at 3000 rpm in an Interna- 
tional refrigerated centrifuge model PR-2, and frozen in aliquots in polypropylene at --20°C. 
The plasma was thawed only once for use. 
Antisera.--Rabbit  anti  whole human  antiserum,  anti  c~2-macroglobulin  antiserum and 
antifibrinogen antiserum  (Behring Diagnostics, Woodbury, N.Y.)  were used in the various 
immunologic assays. 
Methods 
Kaolin activation of plasma arginine esterase was performed by a modification of the Col- 
man technique (3). 10 mg of solid kaolin (Fisher Scientific Company, Fair Lawn, N. J.) was 
added per ml of plasma in plastic tubes at 25°C.  0.1  ml portions were removed at various 
intervals and pipetted into 2.2 ml of 0.1 ~ sodium phosphate buffer, pH 7.5, containing TAMe 
in a final concentration of 0.05 M in an ice bath. In experiments comparing the hydrolysis of 
BAMe and ALMe relative to TAMe, the final substrate concentration used was 0.015 ~  (15). 
In some experiments 0.6  mg SBTI was also  included in the substrate tube. The hydrolysis 
of the substrate was measured by a previously described modification of the Siegelman  tech- 
nique (17, 18). 
Esterolytlc assays of column chromatography fractions of kallikrein preparations and of 
various incubation mixtures of kallikrein, c~2- macroglobulin, SBTI and Ci inactivator were 
performed by a  similar technique. The concentrations of the reactants used are detailed in 
the figure and table legends. 
Acid-treated plasma was prepared as has been described (15, 19). One volume of 1/~ N HC1 
was added to plasma and allowed  to incubate at 25°C for 10 rain before neutralizing with 1 
volume of 1/6  N NaOH  and  1 volume of 0.1 ~  sodium phosphate buffer, pH 8.0.  In kaolin 
activation experiments, 10 mg of solid kaolin per ml acid-treated plasma solution was added 
and 0.4 ml of solutions removed at various intervals for assay of TAMe esterase activity. 
C7 inactivator concentrations in  the plasma of individuals with hereditary angioneurotic 
edema were determined as previously described (18). 
Benzoyl-Dz-arglnine-p-nitroanilide,  (BAPNA)  was used  to  test for  trypsin-like activity 
associated with various kaltikrein and o~2-macroglobulin preparations (20). 
Protein was measured by the Lowry procedure (21) using bovine serum albumin (Pentex, 
Inc., Kankakee, Ill.) as the reference standard. 
Chromatography.--Diethylaminoethyl (DEAE) cellulose  (DE-52,  H. Reeve Angel and Co., 
Inc., Clifton, N.  J.)  was prepared according to the manufacturer's instructions and equili- 
brated with buffers as indicated in the figure legends. Sephadex G-200, 40-120 #  (Pharmacia 
Fine Chemicals Inc., Piscataway, N. J.) was swollen and packed by gravity in citrate-sodinm 
chloride buffer. Blue Dextran 2000  (Pharmacia) was used to determine the void volume of 
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Laboratories, Richmond, Calif. All column chromatographic procedures were carried out at 
4°C. 
Immunodectrophoresis (22), double diffusion analysis (23) and quantitative radial immuno- 
diffusion (24) were performed by established techniques. 
Acrylamlde gel dectrophoresis was performed as previously described (25),  a 4% gel being 
used for the separation of purified a2-macroglobulin. 
Purification  of Plasma  ¢z2-Macmglobulin, Kallikrein., Cls and C1 Inactivator.--~2-macro- 
globulin was purified from  freshly obtained human plasma  by modifications of previously 
described methods  (26-28).  The purification procedure consisted of fractional precipitation 
with polyethylene glycol  and  Rivanol followed  by gel  filtration  chromatography.  Whole 
blood was collected in plastic tubes in 1/6 volume 3.8% sodium citrate containing crude soy- 
bean inhibitor to achieve a final concentration of 0.2 mg per ml in whole blood. All subsequent 
procedures were carried out in polypropylene containers. Following centrifugation the plasma 
coagulation factors II, VII, IX and X  were removed by consecutive adsorption with barium 
chloride and barium sulfate. Two volumes of 0.02 ~  phosphate buffer, pH 7.4, containing 0.1 
NaC1 were added to the adsorbed plasma and 50% polyethylene glycol (PEG) (6000 molec- 
ular weight,  General Biochemicals Div., Chagrin Falls, Ohio)  (29, 30) was added  to  a  final 
concentration of 4% at 0°C. The precipitate contained the bulk of the plasma fibrinogen. The 
concentration of PEG in the supernatant was increased to 12%. The second precipitate con- 
taining the plasma cz2-macroglobulin  was resuspended in 1/]  the original plasma volume of 
0.1  ~  sodium phosphate buffer, pH  7.6.  0.4  volume of 0.5%  Rivanol (K&K  Laboratories, 
Plainview,  N.  Y.)  was  added  to  the crude  resuspended  c¢2-macroglobulin,  the  precipitate 
discarded,  and an additional 0.6 volume 0.5°~o Rivanol was added. This precipitate was ex- 
tracted  with 1/~0 the  original plasma volume of  5%  sodium  chloride  for 30  min, dialyzed 
against  distilled water for 2 hr, then  for  18 hr against 0.85%  sodium  chloride, 0.16%  so- 
dium citrate  (citrate-saline buffer). The  o~2-macroglobulin  comprised  15-25%  of  the  total 
protein of this Rivanol fraction. 
Further purification was achieved by column chromatography on a  5  >(  100 cm agarose 
column (Bio-Gel A-1.Sm, 200400 mesh, Bio-Rad Laboratories, Richmond, Calif.) in citrate- 
saline buffer. The fractions containing o~2-macroglobulin,  as identified by double immuno- 
diffusion analysis using o~2-macroglobulin  antibody, were pooled, precipitated by adding 50% 
PEG to a final concentration of 15%, and resuspended in citrate-saline buffer in a concentra- 
tion of 24 mg cz2-macroglobulin per ml and stored in plastic tubes at 4°C. The total yield was 
about 50% calculated on the basis of a plasma a2-macroglobulin concentration of 200 mg/100 
ml. 
Immunoelectrophoresis of  this product  showed  traces  of gamma  M  macroglobulin and 
haptoglobin in addition to the main o~2-macroglobulin  arc. No C1 inactivator was identifiable 
in this preparation by double immunodiffusion analysis using C[ inactivator antibody gener- 
ously provided by Dr.  Fred  Rosen,  or by a  biochemical assay for this inhibitor (18).  The 
identity of the major protein as the a2-macroglobulin was further established by the ability 
of this preparation to protect a  purified trypsin solution from inhibition by SBTI utilizing 
BAPNA  as  the substrate  (26).  No  BAPNA  hydrolyzing activity was  detected  in  the ¢z2- 
macroglobulin preparation. These preparations had low levels of spontaneous TAMe esterase 
activity averaging 0.07 #moles of TAMe hydrolyzed/min per mg cz2-macroglobulin.  In con- 
trast, oz2-macroglobulin  prepared as described, but without SBTI added  to the freshly col- 
lected whole blood, contained approximately ten times the TAMe esterase activity of  the 
inhibited plasma. In some instances the a2-macroglobulin preparation obtained following gel 
filtration was further purified by preparative electrophoresis on Pevikon (Mercer Chem. Co., 
New York.)  (31) and the o~2-macroglobulin  fractions so obtained contained no other proteins 
identifiable by double diffusion analysis using polyvalent rabbit anfihuman serum antibody. 
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purified from kaolin-activated plasma  or  from  noncontact,  inhibited plasma  by  methods 
similar to the method described. The plasma to be activated by kaolin was collected in poly- 
propylene containers without the addition of SBTI.  Following incubation with  10  mg of 
kaolin per ml plasma at room temperature, the a2-macroglobulin was purified as described. 
Alternately the inhibited plasma was collected in SBTI and Trasylol (compound A-128, pro- 
teinase inhibitor; FBA Medical Research Division of Metachem, Inc., New York)  and all 
buffers used in the purification procedure contained 0.2 mg per ml SBTI and 200-250  units 
Trasylol (15, 32). 
Plasma kallikrein  was purified from outdated plasma by a  method based on  the finding 
that human plasma celite eluate was a  source of crude kallikrein  (33).  Coagulation factors, 
II, VII, IX and X  were removed from the plasma as described in the purification procedure 
for czz-macroglobulin.  The plasma was treated with acid  and neutralized as previously de- 
tailed in order to destroy the plasma kallikrein inhibitors (15, 19,  34).  This procedure in- 
creased the yield of arginine esterase, rat uterine  contracting and PTA-clotting activity in 
the celite eluate by 4-fold as compared to the celite eluate from untreated plasma. Celite, 
20 mg per ml final concentration, (Celite Analytical Filter Aid, Johns-Manville Celite Division, 
Cleveland, Ohio)  was added and mixed with the acid-treated plasma for 15 rain.  The celite 
was washed four times each with twice the plasma volume  of 0.15  •  sodium chloride and 
eluded with a/~  the original plasma volume of 10%  sodium chloride in one of  two  buffers, 
either 0.01  M sodium phosphate buffer,  pH 6.0, or 0.05 ~ sodium carbonate buffer, pH 10.0. 
The eluates were dialyzed against distilled water for  18  hr,  followed  by 48  hr of dialysis 
against large volumes of 0.05 M Tris-chloride, pH 8.0, containing 0.02 M sodium chloride. The 
recovery of TAMe esterase activity, comparing the cellte eluates to the esterase activity of the 
starting kaolin-activated plasma was 18%  at pH 6.0,  and 32% at pH 10.0. The specific ac- 
tivities of the two eluates were 3.8 #moles of TAMe/min per mg at pH 6.0, and 0.7/zmoles 
of TAMe/rain per mg at pH  10.0. Compared to the starting kaolin-activated plasma, this 
represented a 223-fold and 41-fold purification of TAMe esterase activity.  ~ 
The celite eluates obtained at pH 10.0 and 6.0, were further purified by DEAE-cellulose 
chromatography  (Whatman DE  52  preswollen microgranular exchanger). The  eluate was 
applied to a 2.5  >( 30 cm column equilibrated with 0.05 ~  Tris-chloride buffer,  pH 8.0, con- 
taining 0.02 M sodium chloride. The material not absorbed to the column was concentrated 
by pressure ultrafiltration. The specific activity of this material calculated as previously de- 
scribed (35), was 2.1 #moles of TAMe/min per mg protein for the pH 10.0 extracted eluate, 
representing a  200-fold  purification over the starting plasma, and varied between 7.0  and 
10.0 #moles TAMe/min per mg for several different preparations of the pH 6.0 celite eluate. 
The  most highly purified preparations achieved a  900-fold  purification of TAMe  esterase 
activity. This was comparable to the TAMe esterase activity reported for purified plasma 
kallikrein (35). 
The probable identity of the TAMe esterase in these two preparations as plasma kallikrein 
was suggested by the finding that the ratio of hydrolysis of BAMe and ALMa relative to 
TAMe was similar to that described previously for plasma kallikrein  (35).  Both SBTI and 
C1 inactivator in appropriate concentrations inhibited the esterolytlc activity of the DEAE- 
cellulose purified cetite eluates. These preparations were active in stimulating the contraction 
of the rat uterus in the presence of both unheated plasma and plasma heated to 61°C for 30 
min, a  test which distinguishes kallikreiu from PF/dil (36-40).  This activity was inhibited 
by SBTI and C1 inactivator. That the uterine-contracting substance released by the action 
of the kallikrein preparation on heated plasma was a kinin-like material was established by 
the destruction of this activity by incubation with carboxypeptidase B  (Worthington Bio- 
chemical Corp., Freehold, N. J.)  (41). These preparations also induced vascular permeability 
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changes in the skin of guinea pigs. This effect was abolished by preincubafion with C1 inactiva- 
tot, indicating that the active substance behaved as a kallikrein (42). 
The kallikrein preparations contained no detectable plasminogen, plasmin  (43),  C1  (44), 
or clotting factors II, V, VII-X (45), or X  activity (46). No factor VIII or IX activity was 
demonstrated using specifically deficient plasma (47). Factor XI activity was identified using 
specific  PTA  deficient plasma  (48).  A  standard  calibration curve was  established  relating 
arbitrary units of activated PTA to clotting time in which 1 ml of normal plasma contained 
10  PTA units.  Representative PTA concentrations  for  the DEAE-cellulose purified  celite 
eluate extracted at pH 6.0 were 5.2 PTA units/TAMe unit, and for the pH 10.0 preparation, 
7.3  PTA units/TAMe unit. A TAMe unit was defined as that volume which hydrolyzed 1 
#  mole TAMe/min. Although assays could not be performed for Hageman factor due to the 
presence of activated PTA, it is unlikely that significant concentrations were present in the 
kallikrein preparations as human Hageman factor is absorbed to DEAE-cellulose (49, 50). A 
kallikrein preparation containing 20% of the PTA activity of the DEAE-cellulose purified 
material  was  prepared  by  hydroxylapatite  column  chromatography  of  the  celite  eluate. 
Chromatographic procedures were performed as described by Hjert~n (51). The major TAMe 
esterase, kallikrein peak was absorbed to the column and contained 1.1 PTA unit per TAMe 
unit. 
Cis, the activated subunit of the first component of complement, was prepared by a method 
modified from that of Haines and Lepow (18, 52). 
C1 inactivator was purified from human serum according to the method of Pensky (7,  18) 
and its activity measured using acetyl tyrosine ethyl ester as the substrate for purified Cis 
as has been previously described (53, 54).  No c~2-macroglobulin was detectable by immuno- 
diffusion  in the Ci inactivator preparations,  nor did these preparations display trypsin in- 
hibitory activity in the BAPNA assay (20). 
The evolution of kinin-like activity  was assayed by measuring the contraction of a rat uterine 
horn as described in Table III (55). Uterine contractions were measured isotonically with  a 
linear motion transducer,  model ST-2, the transformer of which was supplied  by an  exciter- 
demodulator  (Phipps  and Bird Inc., Richmond, Va). and recorded on a  Bausch and Lomb 
VOM-5 recorder. 
Vascular permeability was measured by a method similar to that described by Miles and 
Wilhelm (56) using depilated female albino guinea pigs weighing 450-600 g which had been 
injected  intravenously with 0.5%  Evans  blue  (Warner-Chilcott,  Morris  Plains,  N.  J.)  in 
amounts of 2.0 ml/kg body weight. Test solutions were injected intradermally as detailed in 
Table IV. 
RESULTS 
The  E~ect  of Soybean  Trypsin  Inhibitor  on  the  Kaolin-Activated  Arginine 
Esterase  Activity of Normal Plasma and  Plasma from Persons  with Hereditary 
Angioneurotic  Edema  (HANE).--Incubation  of  normal plasma  with  kaolin 
(Fig.  1, left panel)  resulted in the development of TAMe  esterase activity sim- 
ilar to that  described by  Colman et al (15).  Peak  esterolytic activity occurred 
at 1 rain of incubation, following which there was a reduction in activity to 50 % 
of peak activity at 5 rain. In a parallel experiment, SBTI was added to the sub- 
strate  solution to study  the effect of this inhibitor on the active enzyme(s).  In 
the presence of SBTI,  the  1 rain peak activity was reduced by 86 %, however, 
proportionally less inhibition by this inhibitor was demonstrated  as the activa- 
tion continued. 334  PETER  C. HARPEL 
Plasma, treated with acid, a procedure known to inactivate plasma inhibitors 
of several proteolytic enzymes (19, 34) was incubated with kaolin and the TAMe 
esterase  activity evolved measured with  and without SBTI added  to the sub- 
strate (Fig. 1, right panel). As has been described (15), no loss of TAMe esterase 
activity occurred with time, which suggests that the decay in esterase activity 
in  nonacid-treated  plasma  was  due  to  the  presence  of plasma  inhibitors.  In 
contrast to the findings in kaolin-activated plasma,  SBTI added to the TAMe 
substrate,  prior  to  the  addition  of  the  kaolin-activated  acid-treated  plasma, 
produced  a  profound reduction in esterolytic activity.  Approximately 89 %  of 
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FIG. 1. The effect of soybean trypsin inhibitor  (SBTI) on the TAMe esterase activity of 
kaolin-activated  plasma  and  kaolin-activated  acid-treated  plasma.  Kaolin,  10 mg/ml, was 
added  to noncontaet  plasma or to acid-treated  plasma  (see Methods for details) in plastic 
tubes at 25°C. 0.1 ml of the plasma mixture, or 0.4 ml of the acid-treated  plasma were re- 
moved at various time intervals and added to 0.1 ~ sodium phosphate  buffer, pH 7.6, at 0°C 
containing TAMe in a final concentration  of 0.05 ~ or TAMe plus 0.6 mg SBTI in a total 
volume of 2.3 ml. 
the esterase activity of acid-treated kaolin-activated plasma was inhibited at 5 
rain by SBTI in comparison to the 63 %  inhibition in nonacid-treated plasma. 
Since partially purified preparations of PTA (factor XI) have been shown to 
possess  arginine  esterase  activity  (57),  and since kaolin  activates  this  enzyme 
in plasma (58),  the possible contribution  of this factor to the kaolin-activated 
plasma TAMe esterase activity was assessed. Confrming previous findings (59), 
PTA-deficient plasma showed a kaolin-activated TAMe esterase curve identical 
with that found in normal plasma.  Furthermore,  the esterase activity assayed 
with SBTI added to the substrate was similar to that found in normal plasma. 
The contribution of PTA to the plasma esterase activation curves was therefore 
probably insignificant. 
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to one kindred with a  clinical history consistent with hereditary angioneurotic 
edema  (HANE)  and  whose  plasma  were  biochemically  and  immunologically 
deficient  in  Ci  inactivator,  were  examined.  A  representative  experiment  in 
which a  Ci inactivator deficient plasma was activated before or following acid 
treatment is presented (Fig. 2). Peak TAMe esterase activity occurred at 1 rain 
and was greater than in normal plasma (Fig. 2, left panel). At 5 rain there was 
a  reduction to 70 %  of peak activity. The TAMe esterase  activity of the four 
patients studied at peak activity (1 rain)  and at 5 rain is presented in Table  I. 
8 
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FIG. 2. The effect of soybean trypsin  inhibitor on the TAMe esterase activity of kaolin- 
activated  plasma  and kaolin-activated  acid-treated  plasma from a patient with  hereditary 
angioneurotic edema (HANE).  Plasma obtained from a patient with no detectable  Ci inac- 
tivator  (see Methods)  was activated  with kaolin,  or acid treated  and activated.  The time 
course of TAMe esterase activation  with and without SBTI added  to the TAMe substrate 
was followed as detailed in Fig. 1. 
The mean decrease in esterolytic activity comparing the 5  and 1 min samples 
was 30.1%. SBTI added to the substrate TAMe caused a 72 % reduction in the 
1 rain peak activity. As demonstrated with normal plasma,  SBTI caused less 
inhibition  as the  activation progressed.  The TAMe esterase  kaolin  activation 
curve of acid-treated HANE plasma (Fig. 2, right panel) paralleled that demon- 
strated for normal plasma.  Acid treatment prevented  the reduction in TAMe 
esterase activity observed with time in untreated HANE plasma. The arginine 
esterase activity of the acid-treated HANE plasma was inhibited by 88 % when 
SBTI was added to the substrate  (Fig. 2, right panel). 
The ratio of hydrolysis of ALMe and BAMe relative to TAMe by normal and 
HANE plasma at peak activation by kaolin (1 rain) and at 5 rain of incubation, 336  PETER  C,  HARPEL 
when decay in activity had occurred, was compared and found to be sirnilar. 
Kaolin-activated  acid-treated  normal  and  acid-treated  HANE  plasma  hy- 
drolyzed the substrates in a  similar fashion. These results supported the con- 
cept  that  the  same  esterase,  or  closely related esterases  were  responsible for 
the enzymic activity in the preparations studied, and suggested that an acid- 
sensitive factor  partially  inhibited the  esterolytic  enzyme  and  protected  it 
from  inhibition by  SBTI.  Since  human plasma  a2-macroglobulin has  been 
reported  to  possess  these  characteristics in relation to  the  enzymes plasmin, 
TABLE  I 
Reduction of Kaolin-Activated  Plasma  TAMe Esterase Activity with  Time and the Effect of 
Soybean Trypsin Inhibitor on this" Activity in Plasma of Individuals  with Hereditary 
Angioneurotic Edema 
Reduction of  Reduction 
of e~terase  C[  TAMe esterase activity:~  esterase activity  activity at 
Patient  inactivator*  at 5 rain.  compared  5 rain with SBTI 
1  min  5  rain  5 rain +  SBTI  to 1 min§  added to substrate  [] 
unils/ml  tzmoles/ml/  hr  %  % 
H.D.  0  127.8  90.3  70.6  29.3  21.8 
B.D.  3.1  120.9  91.3  67.6  24.5  26.0 
C.K.  2.5  113.5  72.5  46.4  36.1  36.0 
F.D.  0  94.5  65.9  48.1  30.3  27.0 
* The concentration of C 1 inacfivator in the patient's plasma was measured by a method 
described in the text (see Methods), the normal concentration being 41.5 4- 8.4 units/ml. 
2.0 ml plasma from each of 4 persons with hereditary  angioneurotic edema was incu- 
bated with 20 mg of solid kaolin, and the TAMe esterase activity evolved with  time was 
determined in duplicate  (see Methods). 0.6 mg of SBTI was added to one set of tubes con- 
taining the TAMe substrate. 
§ The loss of esterase activity at 5 min of kaolin activation  as compared to the 1 rain 
sample is expressed as per cent reduction in esterase activity. 
[I The reduction in esterase activity at 5 rain with SBTI added to the substrate was com- 
pared to that found at 5 rain without the inhibitor and is expressed as per cent reduction in 
activity. 
trypsin and thrombin (28,  60,  61),  the  effect of purified a2-macroglobulin on 
partially purified plasma kallikrein was studied. 
The Effect of Increasing Concentrations of a2-Macroglobulin, CI Inaclivalor and 
SBTI  on  a Constant Concentration  of Purified Plasma Kallikrein  TAMe Ester- 
ase.--Kallikrein  TAMe  esterase  activity was  progressively inhibited by  in- 
creasing concentrations of a2-macroglobulin, CI inactivator and SBTI (Fig. 3). 
Inhibition by c~2-macroglobulin, in the experiment illustrated, was maximal at 
53%  and was  not increased by adding a  4-fold increase in a2-macroglobulin 
concentration. Similar results were obtained utilizing an ~2-macroglobulin  prep- 
aration purified  by Pevikon block  electrophoresis which  contained no  other 
proteins identifiable by double diffusion analysis or by acrylamide gel electro- HUMAN  PLASMA  ALPHA  2-MACROGLOBULIN  337 
phoresis.  A  kallikrein  preparation  was  purified  by  hydroxylapatite  column 
chromatography and contained 20 % of the PTA clotting activity of the prep- 
aration used in Fig. 3 (see Methods). The a2-macroglobulin inhibited the TAMe 
esterase activity of this material in a  manner identical with that shown.  This 
suggested that the PTA found in the kallikrein preparations used played little, 
if any role, in the a2-macroglobulin, TAMe esterase interaction. 
In contrast to a2-macroglobulin, both Ci inactivator and SBTI produced a 
90 %  inhibition of the TAMe esterase activity of the preparations examined. 
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FIG. 3. The inhibition of the TAMe esterase activity of a constant concentration of purified 
plasma kallikrein by serial dilutions of c~2-macroglobulin, C1 inactivator or soybean trypsin 
inhibitor. 0.1  ml of a  kallikrein preparation containing 0.06  mg protein/ml, with a  specific 
activity of 7.7 #moles of TAMe/rain per mg was added to ot2-macroglobulin, to SBTI, or to 
C1 inactivator (50 inhibitor units/mg of protein) in the concentrations indicated, or to citrate- 
saline buffer in plastic tubes and incubated 5 min at 37°C. The incubation volume was 0.3 mL 
After incubation, 2.0 rnl of 0.1 ~[ sodium phosphate buffer, pH 7.5, containing TAMe  (final 
concentration 0.015 M) was added and the hydrolysis of the substrate measured  (see Meth- 
ods). The concentrations of inhibitors used are plotted on a  semilogarithmic scale. 
This was consistent with  the previously reported ability of these inhibitors to 
inactivate kallikrein arginine esterase activity (35, 62, 63). The a2-macroglobu- 
lin failed to inhibit the ATEe hydrolyzing activity of a purified preparation of 
Cis, the activated subunit of the first component of complement. 
DEAE-Cellulose Column Chromatography of Plasma Kallikrein TAMe Ester- 
ase  and  Kallikrein,  a2-Macroglobulin  Incubation  Mixtures.--Purified  plasma 
kallikrein TAMe esterase activity was eluted from DEAE-cellulose with 0.05 
Tris-chloride buffer, pH 8.0, containing 0.02 M NaC1 (Fig. 4, top panel, peak A). 
No further protein or TAMe esterase activity was eluted by a stepwise increase 
in NaC1 concentration to 0.15 M. After incubation of the same concentration 
of kallikrein with a2-macroglobulin, one protein peak was identified following 338  PETER  C.  HARPEL 
DEAE-cellulose chromatography  (Fig.  4,  middle panel,  peak  B)  and  corre- 
sponded to the a2-macroglobulin  peak (bottom panel). No protein or esterolytic 
activity was demonstrable in a location corresponding to the kallikrein protein 
peak, whereas peak B, eluted by 0.15 ~  NaC1, hydrolyzed TAMe. Comparison 
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FIG. 4. DEAE-cellulose chromatography of purified human plasma kallikrein, kallikrein 
plus c~2-macroglobnlin,  and a2-macroglobulin. 0.5 ml of kallikrein containing 1.1 mg of pro- 
tein/ml with a specific activity  of 2.2 #moles of TAMe hydrolyzed/min per mg of protein, was 
applied to a 1.3  X  25 cm column of DEAE-cellulose (DE-52, Whatman)  equilibrated with 
0.05 ~  Tris-chloride buffer containing 0.02 M of NaC1 (top panel). 6 ml fractions were col- 
lected at a flow rate of 18 ml/hr. After fraction 6, the concentration of NaC1 in the eluting 
buffer was increased to 0.15 M. 0.5 ml of kallikrein and 2.0 ml of a2-macroglobulin (8 mg/ml) 
in eluting buffer, or  buffer plus a~-macroglobulin  were incubated  5 min at 37°C and chro- 
matographed under similar conditions (middle and bottom panels). 
of the total esterase activity in peak B  of the kallikrein ~2-macroglobulin mix- 
ture,  following subtraction of  the  spontaneous activity associated  with  the 
purified oe2-macroglobulin peak  to  the  TAMe  activity of  peak  A,  kallikrein 
alone, showed a 47 % loss of activity. The ratio of esterolytic activity of the two HUMAN  PLASMA  ALPHA  2-MACROGLOBULIN  339 
peaks against BAMe and ALMe using TAMe as the reference substrate, was 
similar, and compared to that previously reported for purified plasma kallikrein 
(35). 
Gel Filtration Chromatography of Plasma Kallikrein  and Kallikrein, a2-Macro- 
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FIG. 5. Sephadex 0-200 column chromatography of human plasma kal]ikrein, kallikrein 
plus c~2-macroglobulin, and c~2-rnacroglobulin. 0.8 rn] of kallikrein preparation as described 
in Fig. 4, was applied to at 2.5 X  30 cm column of Sephadex G-200 equilibrated with 0.85~ffo 
sodium chloride, 0.16%  sodium citrate buffer (top panel). 4 ml fractions were collected at a 
rate of 10 rnl per hour. 0.8 rnl of kallikrein plus 1.0 rnl of a2-macroglobulin  (24 mg per ml) in 
citrate-saline  buffer or buffer plus a2-macroglobulin were incubated 5 rnin at 37°C and chrorna- 
tographed under  similar conditions  (middle  and  bottom panels). Blue Dextran 2000 was 
used to indicate the void volume. The hydrolysis of TAMe was measured as described in the 
Methods. 
globulin Incubation Mixtures.--TAMe esterase activity of a kallikrein prepara- 
tion was eluted following Sephadex G-200 chromatography (Fig. 5,  top panel) 
at a position consistent with its reported molecular weight below 200,000  (35). 
Chromatography of the same concentration of ka]likrein incubated with purified 340  PETER  C.  tIARPEL 
a2-macroglobulin produced one peak of TAMe esterase activity (Fig. 5, middle 
panel)  eluted  just  following the void volume.  This  peak corresponded  to  the 
esterase  activity  associated  with  the  a2-macroglobulin  eluted  from Sephadex 
G-200 (Fig. 5, bottom panel). Following incubation of kallikrein and a2-macro- 
globulin, no esterolytic activity could be demonstrated in Sephadex G-200 frac- 
tions in the location of kallikrein  alone.  The ratio of esterolytic activity of the 
two peaks  against BAMe and ALMe using TAMe  as  the reference  substrate 
was  similar.  The  Sephadex  G-200  peaks  containing  TAMe  esterase  activity 
from chromatography of kallikrein,  or a  kallikrein,  a,.,-macroglobulin mixture 
were preincubated with SBTI or Ci inactivator prior to assay (Table II). Both 
inhibitors caused 90 %  or greater inhibition of hydrolysis of TAMe by the kalli- 
TABLE  II 
Effect  of Soybean  Trypsin [nhib#or and Ci lnactivator  on the Hydrolysis  of TAMe by Plasma 
Kallikrein, or a Kallikreln,o~2-Macroglobulin  Mixture after Sephadex  G-200 Chromatography 
Fraction*  TAMe hydrolyzed  Inhibition 
lzmoles/rnl/hr  % 
Kallikrein peak  0.80  -- 
"  plus 0.6 mg SBTI  0.03  96.3 
"  plus 4.0 units C[ inacfivator  0.08  90.0 
¢z2-macroglobulin, kallikrein peak  3.7  -- 
"  "  plus 0.6 mg SBTI  3.0  18.9 
"  "  plus 4.0 units Ci inactivator  3.7  0 
* The fractions  with  peak  TAMe esterase  activity obtained  following Sephadex  G-200 
column chromatography (Fig. 5) were assayed using TAMe as the substrate  in the presence 
of SBTI or Ci inactivator.  0.5 ml of the fractions were incubated 5 rain at 37°C with buffer, 
0.6 mg of SBTI, or 4.0 units of C1 inactivator.  The incubation mixtures were then assayed in 
a final volume of 2.3 ml for residual esterolytic activity using TAMe in a final concentration 
of 0.015 M (see Methods). 
krein peak whereas the ae-macroglobulin,  kallikrein peak was not inhibited by 
Ci inactivator and inhibited 19 % by SBTI. 
The Effect of a  Mixture of a2-Macroglobulin  and CI Inactivator on the TAMe 
Esterase Activity of Kallikrein.--C]  inactivator inhibited  95.2 %  of the TAMe 
esterase  activity  of kallikrein  following 5  min  incubation  whereas  a2-macro- 
globulin inhibited 53.3 %  of the initial  activity under similar conditions. A mix- 
ture of the two inhibitors identical in final concentration with the above experi- 
ments, produced 66.2 % inhibition.  This inhibitory effect was found to be time 
dependent  (Fig.  6).  Inhibition of TAMe esterase  activity increased sharply in 
mixtures  containing  kallikrein  with  C]  inactivator  or  with  oe~-macroglobulin 
during  the  first  3  min  of incubation.  The  combination  of the two  inhibitors 
produced an inhibitory curve which was intermediate  in position as compared 
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Comparison  of the TAMe Esterase Activity Associated with the o~2-Macroglobu- 
lin Prepared from Non-contact,  Inhibited Plasma or Kaolin-Activated Plasma -- 
The  a2-macroglobulin fraction  obtained from inhibitor-treated plasma as  de- 
scibed in the methods, had a  specific activity of 0.005  g  moles TAMe/rain per 
mg, whereas the fraction obtained from kaolin-activated plasma had a  specific 
activity of 1.24  ~ moles/min per mg a2-macroglobtflin, a  240-fold difference in 
activity. Neither  Trasylol,  SBTI,  or purified  Ci  inactivator significantly in- 
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FIG. 6. The effect of time on the inhibition of the  TAMe esterase  activity of kallikrein 
by C1 inactivator, by a2-macroglobulin,  and by a mixture of the two inhibitors. 1.6 ml of a 
plasma kallikrein preparation containing 1.1 mg of protein/ml and a specific activity of 2.2 
#moles of TAMe hydrolyzed/min per mg, were added in duplicate to plastic tubes containing 
0.8 ml of a2-macroglobulln  (8 mg per ml) and 0.8 ml of C[ inactivator (40 units per ml), or 
similar concentrations of a2-macroglobulin  or Ci  inactivator plus phosphate buffer.  The 
mixtures were incubated at 37°C and 0.4 ml portions were assayed at varying time intervals 
for residual TAMe esterase  activity. The per cent inhibition was calculated by comparing 
the residual esterase activity in the inhibited incubation mixtures to the uninhibited kalli- 
krein preparation. 
hibited  this  TAMe  esterase  activity. The  relationship of the  TAMe  esterase 
activity of the ~2-macroglobulin to kallikrein was suggested by the finding that 
the ratio of hydrolysis of ALMe and BAMe, relative to TAMe, resembled that 
documented for purified plasma kallikrein. Further purification of these frac- 
tions  by  agarose  column  chromatography,  followed  by  Pevikon  preparative 
electrophoresis, showed that all the esterolytic activity was associated with the 
~x2-macroglobulin. 
E~ect of a2-Macroglobulin on Rat Uterus Contracting Activity of Plasma Kalli- 
krein.--Increasing  concentration  of o~2-macroglobulin in  a  preincubation mix- 
ture,  progressively inhibited the ability of a  constant concentration of plasma 342  PETER  C. I-IARPEL 
kallikrein to release rat uterine contracting substances from plasma previously 
heated to 61°C for 30 rain (Table III). The addition of 0.1  mg SBTI to a  pre- 
incubation  mixture of kallikrein  and  buffer inhibited the  uterine  contraction. 
That the biologically active substance responsible for uterine contractions was 
most likely a  kinin was suggested by the finding that the addition of carboxy- 
peptidase B  to  a  preincubation mixture of kallikrein and heated plasma  sub- 
TABLE II[ 
Effect of a2-Macroglobulin  on Kallikreln-Induced Rat  Uterine Contractions 
Initial incubation mixture*  Uterine contraction 
a~-macroglobulin  Kallikrein  Citrate-saline buffer 
ml  mg/ml  ml  ml  mm 
0.20  2.4  +  0.2  +  0.10  0 
0.10  "  +  "  +  0.20  0 
0.15  1.2  +  "  +  0.15  29 
0.10  "  +  "  +  0.20  60 
0.05  "  +  "  +  0.25  76 
0  "  +  "  +  0.30  108 
0.2  ml a2-macroglobulin,  1.2  mg/ml, added  to  uterine  bath prior to 
addition  of 0.2 ml kallikrein 
110 
ng 
Bradykinin,  50  31 
"  75  71 
"  100  101 
* Plasma kallikrein containing 0.08 mg of protein/ml and a specific activity of 4.2 #moles 
of TAMe/rain per mg, was preincubated  5 rain at 25°C in plastic tubes with varying concen- 
trations  of ~2-macroglobulin as indicated. The final volume of the mixture was 0.5 ml. 0.4 ml 
of the incubation mixture was added to a 29°C bath containing 20 ml of de Jalon's solution in 
which was suspended a rat uterine  horn  segment obtained  from  250-300 gm virgin  rats in 
estrus. Prior to the addition of the incubation mixture, 0.1 ml of plasma substrata  previously 
heated to 61°C for 30 rain had been added. Uterine contractions  were recorded as detailed in 
Methods. The height of the amplified contractions  in millimeters is recorded in the table. In 
the absence of plasma  substrate  neither ~x2-macroglobulin nor kallikrein caused uterine  con- 
tractions. Bradykinin was added to the uterine bath without the plasma substrata  as a control. 
strate  prevented  uterine  contractions,  a2-macroglobulin  added  to  purified 
bradykinin in  a  preincubation mixture did not affect the amplitude of uterine 
contractions as compared to bradykinin alone. 
The Effect of ~2-Macroglobulin  on the  Vascular Permeability Induced  by Kalli- 
krein.--The  vascular permeability-inducing effect of purified plasma kallikrein 
was  completely  inhibited  by  incubation  with  a2-macroglobulin  (Table  IV). 
That the permeability-inducing effect was due to the enzymic activity of kalli- 
krein was suggested by its inhibition by purified Ci inactivator. C[ inactivator HUMAN  PLASMA  ALPHA  2-MACROGLOBULIN  343 
has been shown to inhibit kallikrein but not to inhibit the kinins generated by 
the enzyme (8). 
The  Uterine-Contracting  and  Vascular  Permeability-Inducing  Activities  of 
Fractions Obtained Following DEAE-Cellulose Column Chromatography  of Plasma 
Kallikrein  and  Kallikrein,  a2-Macroglobulin  Incubation  Mixtures.--Chroma- 
tography of three  incubation mixtures  of kallikrein,  kallikrein  plus a2-macro- 
globulin  and  a2-macroglobulin  was  performed  as  described  in  Fig.  4.  The 
fractions  obtained  were  tested  for uterine-contracting  and  vascular  permea- 
bility-inducing  activities.  These  activities  were found in association with  the 
TAMe esterase  peak of the kallikrein  preparation.  No fraction obtained from 
TABLE IV 
The Effect of c~2-Macroglobulin Upon the Vascular Permeability Producing Effect of Kalllkreln 
Permeability  Mixture tested*  activity  (mm):[: 
Buffer  4.2 
a2-macroglobulin  4.9 
C1 inactivator  3.4 
Kallikrein  8.6 
"  +  c~2-macroglobulin  4.4 
"  +  Ci inactivator  4.0 
* 1 ml mixtures, containing 0.5 ml 0.05 g  Tris,  pH 8.0, 0.02 ~  NaC1 buffer and 0.5 ml 
a2-macroglobulin  (8 mg/ml), 0.5 ml CI inactivator  (40 units/ml), kallikrein  (0.06 mg/ml, 
SA 7.7 #  moles TAMe hydrolyzed/min/mg)  or equal  volumes of kallikrein  and these in- 
hibitors  were incubated  at 37°C for 5 min and 0.1 ml aliquots  injected  into each of four 
guinea pigs. At 30 mill the longest diameter of the blue spot and its perpendicular  diameter 
were measured on the surface of the skin. 
The diameters were averaged and the permeability activity was expressed as the mean 
of the diameters. 
chromatography of the kallikrein,  a2-macroglobulin mixture possessed biologic 
activity. 
DISCUSSION 
These studies have shown that the a~-macroglobulin is an inhibitor  of par- 
tially purified human plasma kallikrein.  The inhibition of the arginine esterase 
activity, rat uterine-contracting  and vascular permeability-inducing  effects of 
kallikrein is accompanied by the formation of a high molecular weight complex 
between the enzyme and the  a2-macroglobulin. These results support Becker's 
speculation that there may be another plasma inhibitor of kallikrein in addition 
to CI inactivator  (12).  This thesis was suggested by the study of individuals 
with hereditary angioneurotic edema who have a  deficiency of a specific heat- 
and  acid-labile  a2-neuraminoglycoprotein  designated  CI  inactivator  (5-7,  42, ~ZI4  PETER  C. ~ARPEL 
64).  Although  Ci  inactivator effectively inhibits both kallikrein,  PF/dil  and 
Ci in purified systems (9, 54), the experimental evidence now available suggests 
that activation of kallikrein and the permeability globulin system, if it occurs 
in hereditary angioneurotic edema,  is  not proportionately as  great  as  is  the 
activation of the complement system (12). 
These findings may be explained by the results of the present investigation 
which indicate that plasma deficient in Ci inactivator inhibits plasma kaUikrein. 
This was established by studying the kaolin-induced TAMe esterase activity 
of normal  plasma  and  of plasma  obtained from individua]s  with  hereditary 
angioneurotic edema.  Recent data  of Colman,  Mattler,  and  Sherry (15,  35) 
have indicated that  the kaolin-activated plasma arginine esterase is identical 
with plasma kallikrein. They demonstrated that maximal activation of TAMe 
esterase activity by kaolin  occurred at  1 min in both normal plasma  and in 
hereditary  angioneurotic  edema  plasma.  Our  studies  have  shown  that  this 
activity falls to 50% of peak activity at 5 min of kaolin activation in normal 
plasma and to 70 % of peak activity in the plasma of four patients with heredi- 
tary angioneurotic edema.  That  Ci  inactivator was  not  responsible for this 
inhibitor)" effect was indicated by the absence of this inhibitor in the plasma of 
these individuals as measured by double diffusion immunoassay using a mono- 
specific antibody preparation, and by the finding of from 0 to 10% of normal 
inhibitor levels as determined by a sensitive biochemical assay. 
The kaolin-activated TAMe  esterase in  normal  plasma  and  in  hereditary 
angioneurotic edema plasma was less  susceptible  to inhibition by SBTI at 5 
rain of activation than at the 1 min peak activity. This decrease in susceptibility 
was quantitatively similar in normal and in  CI  inactivator-deficient plasma. 
In contrast, the kallikrein TAMe esterase activated by kaolin in acid-treated 
normal  and hereditary angioneurotic edema plasma  did not lose its  activity 
with time and retained its susceptibility to inhibition by SBTI. Acid treatment 
therefore, apparently destroyed an inhibitor in normal and in C1 inactivator- 
deficient plasma which caused a reduction in esterolytic activity and which also 
protected the enzyme from the inhibitory effect of SBTI. This conclusion was 
supported by data which made it unlikely that an enzyme other than kallikrein 
was responsible for the resistence to SBTI observed in the 5 rain sample of the 
kaolin-activated plasma.  The ratio  of hydrolysis of two synthetic ester sub- 
strates relative to TAMe by the arginine esterase at 1 and at 5 rain of kaolin 
activation in normal plasma, in hereditary angioneurotic edema plasma, and in 
acid treated normal  and hereditary angioneurotic edema plasma was  similar. 
This strongly suggests that the same enzyme, kallikrein, was responsible for the 
esterase activity in each sample. This was a particularly important observation 
since it has been demonstrated that activation of Hageman factor in hereditary 
angioneurotic edema plasma resulted in the conversion of the first component 
of complement into the active esterase, Ci  (65).  C1, a TAMe esterase which is HUMAN  PLASMA  ALPHA  2-MACROGLOBULIN  345 
not inhibited by SBTI (44), has been found to hydrolyze acetyl-L-lysine  methyl 
ester (ALMe) (66). This substrate is more susceptible to the action of Ci than 
is TAMe. Since the ratio of hydrolysis of ALMe relative to TAMe remained 
unchanged in the hereditary angioneurotic edema plasma,  significant activa- 
tion of Ci during the time period of the kaolin activation did not occur. 
The a~-macroglobulin purified from human plasma has been shown to form 
a complex with the proteases thrombin (61), plasmin (60, 67), and trypsin (28), 
to partially inhibit their esterolytic activity, and to almost totally inhibit their 
proteolytic activity. Mter complex formation, the esterolytic activity of the 
bound trypsin and plasmin was no longer inhibited by SBTI (28, 67, 68). Acidi- 
fication of purified a2-macroglobulin preparations to pH 3.0,  resulted in com- 
plete loss of trypsin binding activity (26). The present investigation has shown 
that the a2-macroglobulin inhibits the esterolytic and proteolytic activity of 
purified plasma kaUikrein in a manner analogous to that. reported for thrombin, 
plasmin,  and  trypsin.  The  kallikrein preparations  used had  esterolytic and 
biologic  activities  as  previously described  for  plasma  kallikrein  and  corre- 
sponded to the major plasma kallikrein not absorbed to DEAE-cellulose (35, 
62, 69). Incubation of kaUikrein and a2-macroglobulin resulted in a concentra- 
tion  and  time-dependent inhibition of kallikrein TAMe  esterase  activity to 
approximately  50%.  The  presence  of  significant  concentrations  of  plasma 
thromboplastin antecedent (PTA) clotting activity in the purified plasma kalli- 
krein preparation was shown to have no significant effect on the ol2-macroglobu- 
lin,  kallikrein inhibition curve.  Results of anion exchange and gel  filtration 
chromatographic  experiments  indicated  that  the  purified  a~-macroglobulin 
formed a  complex with plasma kallikrein similar to that formed between the 
inhibitor and trypsin. The esterolytic activity of this complex was resistant to 
inhibition by both SBTI and purified Ci inactivator, whereas these inhibitors 
blocked 95 %  or more of the TAMe esterase activity of the kallikrein peak. 
A mixture of CI inactivator and ¢z~-macroglobulin, in concentrations equiva- 
lent to the concentration measured in normal plasma, interacted with the kal- 
likrein TAMe esterase in purified systems. As previously reported, the inhibi- 
tion of kallikrein TAMe esterase activity of ci inactivator was progressive with 
time (63).  The a2-macroglobulin induced inhibition of kallikrein esterase ac- 
tivity was found to be similarly time dependent. The inhibition curve produced 
by both inhibitors together was intermediate between that found for ci inacti- 
vator and a,-macroglobulin alone and suggested that the two inhibitors com- 
peted  for  kallikrein. Thus  the  a2-macroglobulin partially protected  the  es- 
terolytic activity of kallikrein from inhibition by Ci inactivator. These results 
may explain the differences in the kaolin activation curves obtained with normal 
and with hereditary angioneurotic edema plasma and provide support for the 
thesis that the a2-macroglobulin is the acid-labile plasma fractor which par- 
tially inhibited  and protected the  kaolin-activated plasma  arginine  esterase 346  PETER  C.  tIA1LPEL 
from inhibition by SBTI.  The greater inhibition  of kaolin-activated normal 
plasma esterase at 5 min as compared to the hereditary angioneurotic edema 
plasma esterase (50 verses 30%) may reflect, in the case of normal plasma, the 
interaction between  kallikrein,  Ci  inactivator, and o~-macroglobulin. In  the 
plasma deficient in Ci  inactivator, the decay in TAMe esterase activity may 
be entirely due to interaction with o~2-macroglobulin. This reduction in esterase 
activity cannot, therefore, be used as a measurement for Ci inactivator levels 
as has recently been proposed (3). 
Additional indirect evidence for the ability of the ~2-macroglobulin to form 
a complex with kallikrein in plasma was obtained by purifying o~2-macroglobulin 
from plasma to which inhibitors of kallikrein and of its activation were added. 
The purified a2-macroglobulin obtained from kaolin-activated plasma contained 
240 times the TAMe esterase activity of the (~2-macroglobulin  derived from the 
inhibited plasma.  The ratio of its activity toward synthetic basic amino acid 
esters compared to TAMe suggested its relationship to purified kallikrein. These 
results extend the findings of Howard (26) who found an a2-macroglobulin- as- 
sociated  TAMe esterase which  could be separated from esterase-inactive ~2- 
macroglobulin  by low ionic strength precipitation.  Further investigations by 
Dyce  et  al.  (70),  reported in  abstract  form, have  shown  that  an  esterolytic 
enzyme with properties of a kallikrein can be dissociated from this purified oz2- 
macroglobulin. 
The a~-macroglobulin was found to inhibit the rat uterine-contracting ability 
of a kallikrein preparation as well as its vascular permeability- producing effect 
(71).  Fractions of incubation mixtures of kallikrein,  kallikrein and a2-macro- 
globulin,  and a~-macroglobulin obtained by DEAE-cellulose chromatography 
were assayed for these  two biologic activities.  Following incubation with o~2- 
macroglobulin, the kallikrein TAMe esterase, uterine-contracting and vascular 
permeability-inducing activities were no longer eluted in fractions where kalli- 
krein  activity was found. This loss  of biologic activity paralleled  the loss of 
TAMe esterase activity and provided additional evidence both for the identity 
of kallikrein as the TAMe esterase studied, and for the binding of biologically 
active kallikrein by the o¢~-macroglobulin. 
The finding  that  the  human  plasma  oe2-macroglobulin  complexes with the 
major plasma kallikrein to partially inhibit its esterolytic activity and to com- 
pletely  inhibit  its  uterine-contracting  and  vascular  permeability-inducing 
activities has  potential  relevance to various human  disease  states.  The two 
plasma inhibitors,  C[  inactivator and a2-macroglobulin, have been shown in 
this study to compete for the enzyme kallikrein in purified systems. While the 
biologic function of the a2-macroglobulin is unclear, it has been established that 
the enzymes thrombin and plasmin are inhibited in vitro by this plasma glyco- 
protein. Thus the o~-macroglobulin may serve as an inhibitor of three different 
plasma  enzyme systems:  the kallikrein,  the  coagulation,  and  the fibrinolytic HUMAN  PLASMA  ALPHA  2-MACROGLOBULIN  347 
enzyme system. Ganrot (72)  has shown that thrombin and plasmin may be 
bound to the same binding group of the a2-macroglobulin and that competition 
between these enzymes for this site can be demonstrated in vitro. Ganrot has 
postulated that such competition, if it exists in vivo might be an important 
mechanism controlling the equilibrium between intravascular coagulation and 
fibrinolysis in pathologic states. No information is yet available on the binding 
site of a2-macroglobulin for kallikrein or its possible interaction with the throm- 
bin and plasmin binding sites.  The formation of a kallikrein, o!2-macroglobulin 
complex with the esterolytic activity of the enzyme protected from Ci inacti- 
vator  raises  the  question  of  the  physiologic significance of such  a  complex. 
James, Taylor, and Fudenberg (73) have suggested that the interaction of a2- 
macroglobulin with plasmin might provide a reservoir of enzyme free from the 
action of circulating inhibitors. 
Evidence suggesting that in vivo interactions may occur between several 
components of the coagulation, fibrinolytic, kallikrein, and complement systems 
has been provided by Donaldson. She has shown that activation of Hageman 
factor or of the fibrinolytic enzyme system in the plasma of patients with he- 
reditary angioneurotic edema was accompanied by conversion of the first com- 
ponent of complement into its esterase,  Ci  (65, 74).  The pathway by which 
Hageman factor activates Ci  is obscure,  however, both the fibrinolytic and 
kallikrein systems may be involved. Several investigations (75,  76) have sup- 
ported the concept that plasma fibrinolytic activity can be induced by Hageman 
factor activation. Kallikrein, which is also activated by Hageman factor (32), 
has been shown to convert plasminogen into the active enzyme plasmin (77). 
Plasmin has been shown to activate the first component of complement (44, 
78) and kallikrein may also directly activate Ci (63, 65). In addition, plasmin 
destroys the inhibitory activity of Ci inactivator and alters it immunoelectro- 
phoretic characteristics (25). 
The  ability of  the  a2-macroglobulin,  a  known  inhibitor  of  thrombin  and 
plasmin, to inhibit plasma kallikrein provides another example of an interrela- 
tionship between the coagulation, fibrinolytic, and kaJlikrein pathways. This 
inhibitor may play an important role in modulating the relative participation 
of these complex enzyme systems in human pathophysiologic states. 
SUMMARY 
Activation of plasma kallikrein arginine esterase activity by kaolin resulted 
in peak activity at 1 rain of incubation and a 50 % reduction in activity at 5 rain 
in normal plasma, and 30 % reduction in the plasma of patients with hereditary 
angioneurotic edema who lacked the Ci inactivator. The peak esterolytic activ- 
ity was inhibited by soybean trypsin inhibitor whereas the 5 rain activity was 
resistant to this inhibitor. Acid treatment of normal and hereditary angioneu- 
rotic  edema plasma destroyed the factor responsible for the fall in  esterase 348  PETER  C.  HARPEL 
activity at 5 min and the factor which rendered  the esterase  resistant  to soy- 
bean  trypsin  inhibitor. 
Purified a2-macroglobulin inhibited approximately 50 % of the TAMe esterase 
activity of purified plasma kallikrein without changing its activity toward basic 
amino acid esters.  The interaction between the ~2-macroglobulin and kallikrein 
resulted in alterations in the gel filtration chromatographic pattern of the TAMe 
esterase and biologic activity of kallikrein, indicating that kallikrein was bound 
to the a2-macroglobulin. The TAMe esterase activity of this complex, isolated 
by column chromatography, was resistant to Ci inactivator and SBTI. Studies 
of incubation mixtures  of kallikrein,  ~2-macroglobulin and  C] inactivator sug- 
gested that these inhibitors compete for the enzyme, and that the ~.~-macroglob- 
ulin partially protects the esterase  activity  of kallikrein  from  Ci  inactivator. 
The  a2-macroglobulin  isolated  from  kaolin-activated  plasma  possessed  240 
times  the  esterolytic  activity  of  the  ~2-macroglobulin  purified  from  plasma 
treated with inhibitors of kallikrein and of its activation. The o~-macroglobulin 
blocked  the  uterine-containing  activity  and  vascular  permeability-inducing 
effects of plasma kallikrein.  These studies suggest that the oe2-macroglobulin is 
a  major plasma inhibitor of kallikrein  and provide a new example of an inter- 
relationship  between  the  coagulation,  fibrinolytic,  and  kallikrein  enzyme sys- 
tems. 
These studies were performed with the invaluable technical assistance of Mr. Ben Denson 
and Mr. Tsun-San  Chang. We wish to thank Dr.  Ralph Nachman for reviewing the manu- 
script and for his valuable suggestions. We are indebted  to Drs. Paul Mitchell and Stanley 
Vickers for referring patients H. D. and B. D. to us. 
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